US7170811035
© BusinessWire
12.12.2025
PFE
LISTED
NYSE
Pfizer Declares First-Quarter 2026 Dividend
News Preview
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by P...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
PFE
LISTED
NYSE
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic b...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
PFE
LISTED
NYSE
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
News Preview
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
06.12.2025
PFE
LISTED
NYSE
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
News Preview
Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. H...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
01.12.2025
PFE
LISTED
NYSE
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose of the call is to provide Pfizer’s full-year 2026 financial guidance.
To view and listen to the webcast, visit our web site at www.pfizer.com/inv...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2025
PFE
LISTED
NYSE
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
News Preview
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda Q...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
PFE
LISTED
NYSE
Pfizer Completes Acquisition of Metsera
News Preview
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.
“This strategic milestone represents more than a transaction—it's a deliberate investment in the f...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
PFE
LISTED
NYSE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT.
To view and listen to the webcast, visit our web site at www.pfizer.c...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
PFE
LISTED
NYSE
Pfizer Responds to Delaware Chancery Court Ruling
News Preview
Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk.
“We remain confident in the merits of our claims a...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
PFE
LISTED
NYSE
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
News Preview
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
“I am proud of Pfizer’s leadership as the first in our industry to reach an agreemen...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
PFE
LISTED
NYSE
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
News Preview
Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.
The lawsuit asserts that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by Novo Nordisk to protect its...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2025
PFE
LISTED
NYSE
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
News Preview
Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreeme...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
31.10.2025
PFE
LISTED
NYSE
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
News Preview
Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).
The termination of the waiting period under the HSR Act s...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
PFE
LISTED
NYSE
Pfizer Addresses Proposal for Metsera
News Preview
Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent a...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
PFE
LISTED
NYSE
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
News Preview
Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also kn...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
PFE
LISTED
NYSE
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 mon...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
PFE
LISTED
NYSE
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
News Preview
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer
Unprecedented survival results from pivotal Phase 3 EV-303 trial...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
PFE
LISTED
NYSE
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
News Preview
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, bo...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
PFE
LISTED
NYSE
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
News Preview
Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.
“IDWeek 2025 offers a cr...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
PFE
LISTED
NYSE
Pfizer Declares Fourth-Quarter 2025 Dividend
News Preview
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company’s common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
PFE
LISTED
NYSE
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
News Preview
Pfizer Inc. (NYSE: PFE) today announced a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America’s role as the global leader in biopharmaceutical innovation.
In response to the four points covered in the President’s July 31st letter, Pfizer has...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
PFE
LISTED
NYSE
Hearing Against Pfizer Set For 29 September In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
News Preview
A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. I...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2025
PFE
LISTED
NYSE
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
News Preview
Pfizer Inc. (NYSE: PFE) will highlight data across its extensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. Data from more than 45 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 11 oral/mini oral presentations and fiv...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2025
PFE
LISTED
NYSE
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2025 Performance Report, to be issued that mo...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
PFE
LISTED
NYSE
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
News Preview
Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portf...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
PFE
LISTED
NYSE
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
News Preview
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY® (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and olde...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
PFE
LISTED
NYSE
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
News Preview
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and old...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
PFE
LISTED
NYSE
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
News Preview
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent CO...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
PFE
LISTED
NYSE
Pfizer Completes Licensing Agreement with 3SBio
News Preview
Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio’s proprietary CLF2 platform. This agreement...
Themefolio
Profiler
Peergroup
© BusinessWire
10.07.2025
PFE
LISTED
NYSE
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
News Preview
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitiv...
Themefolio
Profiler
Peergroup
© BusinessWire
26.06.2025
PFE
LISTED
NYSE
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
News Preview
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HY...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
PFE
LISTED
NYSE
Pfizer Declares Third-Quarter 2025 Dividend
News Preview
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
PFE
LISTED
NYSE
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2025 Performance Report, to be issued that mor...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
PFE
LISTED
NYSE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time.
To listen to the webcast, visit our web site at www.pfizer.com/...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
PFE
LISTED
NYSE
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a B...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
PFE
LISTED
NYSE
Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
News Preview
A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States Courthouse is Pensacola, Florida. The litigation is being brought on behalf of women in the USA who developed meningiomas after receiving at least 4 consecutive injections of Pfizer’...
Themefolio
Profiler
Peergroup
© PR Newswire
22.05.2025
PFE
LISTED
NYSE
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
News Preview
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
PFE
LISTED
NYSE
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
News Preview
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
PFE
LISTED
NYSE
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
News Preview
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1).
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
“We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving impr...
Themefolio
Profiler
Peergroup
© BusinessWire
26.04.2025
PFE
LISTED
NYSE
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder canc...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
PFE
LISTED
NYSE
Pfizer Declares Second-Quarter 2025 Dividend
News Preview
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfiz...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
PFE
LISTED
NYSE
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
News Preview
Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral prese...
Themefolio
Profiler
Peergroup
© BusinessWire
16.04.2025
PFE
LISTED
NYSE
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
News Preview
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract...
Themefolio
Profiler
Peergroup
© BusinessWire
14.04.2025
PFE
LISTED
NYSE
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
News Preview
Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.
Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharm...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
PFE
LISTED
NYSE
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
News Preview
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
PFE
LISTED
NYSE
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
News Preview
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individu...
Themefolio
Profiler
Peergroup
© BusinessWire
18.03.2025
PFE
LISTED
NYSE
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morn...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
PFE
LISTED
NYSE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time.
To listen to the webcast, visit our web site at www.pfizer.com/investors....
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
PFE
LISTED
NYSE
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), demonstrating a statistically significant and clinically meaningful improvement in over...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
PFE
LISTED
NYSE
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
News Preview
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), includ...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
PFE
LISTED
NYSE
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
News Preview
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRU...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
PFE
LISTED
NYSE
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
News Preview
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024.
The fourth-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfiz...
Themefolio
Profiler
Peergroup
© BusinessWire
03.02.2025
PFE
LISTED
NYSE
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
News Preview
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) harboring a B...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
PFE
LISTED
NYSE
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
News Preview
Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 13-15 in San Francisco, California. Data from more than 20 company-sponsored, investigator-sponsored, and collaborative research abstracts...
Themefolio
Profiler
Peergroup
© BusinessWire
25.01.2025
PFE
LISTED
NYSE
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, th...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
PFE
LISTED
NYSE
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder ca...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
PFE
LISTED
NYSE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PST.
To view and listen to the webcast, visit our web site at www.pfizer.com/inves...
Themefolio
Profiler
Peergroup
© BusinessWire
20.12.2024
PFE
LISTED
NYSE
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
News Preview
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
PFE
LISTED
NYSE
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
News Preview
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2024 Performance Report, to be...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
PFE
LISTED
NYSE
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
News Preview
Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1). The accompanying presentation can be found at www.pfizer.com/investors.
Full-Year 2025 Revenue Guidance(1)
Pfizer anticipates full-year 2025 revenues to be in the range of $61.0 to $64.0 billion, which includes t...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
